Prescient Therapeutics Launches $7 Million SPP to Propel PTX-100 Development

• SPP priced at $0.065 per share, 18.8% discount to 10-day VWAP
• Funds targeted to progress PTX-100 past key 2026 clinical milestone
• Eligible shareholders can invest up to $30,000 without brokerage
• Potential follow-on placement to sophisticated investors post-SPP
• PTX-100 holds FDA Orphan and Fast Track designations for T-cell lymphomas

Capital Raise Targets Next Phase of PTX-100 Development

Prescient Therapeutics (ASX:PTX) has kicked off a Share Purchase Plan (SPP) aiming to raise up to $7 million at 6.5 cents per share, marking an 18.8% discount to the 10-day volume weighted average price. The raise is designed to fund the advancement of its lead oncology candidate, PTX-100, beyond a critical Dose Optimisation Committee review scheduled for the second half of 2026. This milestone will serve as a key checkpoint before the company progresses to subsequent development stages.

Shareholder Participation and Terms

Eligible shareholders registered as of 24 August 2026 can apply for up to $30,000 worth of shares without incurring brokerage or transaction fees. The offer opens on 26 August and closes on 8 September 2026, with shares expected to be allotted mid-September. The discounted price also represents a 9.7% markdown from the last trading price, providing an incentive for existing investors to deepen their holdings.

Clinical Progress and Regulatory Momentum

PTX-100 is a first-in-class targeted therapy aimed at inhibiting the enzyme geranylgeranyl transferase-1, disrupting oncogenic Ras pathways implicated in up to 22% of cancers. The asset has shown encouraging safety and early efficacy signals in Phase 1 and Phase 1b studies, particularly in T-cell lymphomas. It has secured Orphan Drug Designation and Fast Track status from the US FDA for cutaneous T-cell lymphoma (CTCL), underpinning its potential in a US$1.2 billion market opportunity. The Phase 2a trial is currently recruiting globally, with sites active in Australia, the US, and Italy, and patient enrolment meeting targets.

Use of Proceeds and Strategic Flexibility

Beyond advancing PTX-100, funds will support general working capital, business development, and portfolio management, including potential evaluation of complementary pipeline assets. The company retains the right to conduct a follow-on placement to sophisticated investors if demand exceeds the SPP capacity. This approach provides financial flexibility while managing dilution for retail shareholders.

Risks and Investor Considerations

Prescient is transparent about the speculative nature of investing in clinical-stage biotech, highlighting risks including clinical trial outcomes, regulatory approvals, funding requirements, and competitive pressures. The company also notes potential impacts from proposed changes to the Australian Research and Development Tax Incentive, which has been a meaningful cash inflow source. Investors are cautioned that the market price may fluctuate during the offer period and that the SPP shares may trade below the issue price post-allotment.

Engagement with Shareholders

CEO James McDonnell will host a live shareholder briefing on 28 August to discuss the SPP details, use of funds, and the company’s development plans. This engagement underscores Prescient’s commitment to transparency as it navigates critical clinical and commercial milestones in the coming year.

Bottom Line?

Prescient’s $7 million SPP is a strategic move to sustain momentum in PTX-100’s clinical journey, but investors should weigh the inherent biotech risks and monitor the upcoming Dose Optimisation Committee review closely.

Questions in the middle?

• Will the Dose Optimisation Committee review deliver positive clinical data to justify further investment?
• How might proposed changes to the R&D Tax Incentive affect Prescient’s future funding needs?
• What appetite will sophisticated investors show for a follow-on placement post-SPP?